On the other hand, our observations reinforce once again the concern, already reported in other cancer settings [44,67], that the design and testing of a multitarget therapy for Notch-dependent T-ALL, focused on NF-κB, should carefully consider the pleiotropic effects of systemic and unspecific NF-κB inhibitors, such as the IKK inhibitors [68,69,70,71]. The gene discussed is NFKB1; the disease is cancer.